Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:127:224-234.

TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE

Brian H Annex  1 , George A Beller  1
Affiliations
Review

TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE

Brian H Annex et al. Trans Am Clin Climatol Assoc. 2016.

Abstract

Atherosclerosis is the leading cause of morbidity and mortality in the Western world. Peripheral artery disease (PAD) has been less studied then coronary artery disease but is nearly as common. PAD impairs blood flow to the leg(s) and causes functional impairment, leg pain, and amputation. The last drug approved for PAD was in 1999. Blood flow to leg proceeds through one major artery and in PAD total occlusions in the course of that vessel are common. Thus, the extent of new blood vessel growth determines a patients' clinical course. Promoting the growth of new blood vessels (therapeutic angiogenesis) was a major goal of therapy. Results from studies using cytokine growth factors have shown disappointing results. Using clinical and preclinical studies, our laboratory has identified several novel therapeutic approaches. One, a modulator of innate immunity, will be reviewed as an approach that has the potential to create new therapies for PAD.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: None disclosed.

Figures

Fig. 1
Fig. 1
This figure demonstrates how the identification of new agents, new approaches for “gene” delivery, and constant reassessment of outcomes in human and preclinical trials are used to identify new approaches to treat peripheral artery disease.
Fig. 2
Fig. 2
Lists the recent papers from our group where new and unexpected targets developed from the integrated translational research program.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Heart Association Heart Disease and Stroke Statistics. https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/doc... .
    1. Wennberg PW. Approach to the patient with peripheral arterial disease. Circulation. 2013;128:2241–50. - PubMed
    1. Peacock JM, Keo HH, Duval S, et al. The incidence and health economic burden of critical limb ischemia and ischemic amputation in Minnesota 2005–2008. Prev Chronic Dis. 2011;8:A141. - PMC - PubMed
    1. Rosamond WD, Chambless LE, Heiss G, et al. Twenty-two–year trends in the incidence of myocardial infarction, coronary artery disease mortality, and case fatality in 4 US communities 1987–2008. Circulation. 2012;125:1848–57. - PMC - PubMed
    1. White C. Intermittent claudication. N Engl J Med. 2007;356:1241–50. - PubMed

MeSH terms

Substances

LinkOut - more resources